Stay updated on Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Sign up to get notified when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.

Latest updates to the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has updated its date references, removing several dates from 2024 and adding new dates in 2025 and 2026.SummaryDifference0.5%
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to include new information about metastatic melanoma and the involvement of Bristol-Myers Squibb, while significant details regarding the study's dosing and inclusion criteria have been removed.SummaryDifference33%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adaptive Dosing of Ipilimumab and Nivolumab Clinical Trial page.